title: Role of histamine in short- and long-term effects of methamphetamine on the developing mouse brain.
abstract: With the rise in methamphetamine (MA) use among women of childbearing age, the potential consequences of MA exposure to the developing brain for cognition in adulthood is a major concern. Histamine might mediate these MA effects. Following MA administration in neonatal mice, histamine levels in brain were elevated and the hypothalamic-pituitary-adrenal axis was activated. Co-administration of MA with the H3 receptor agonist immepip antagonized these effects. The effects of MA on histamine levels and on hypothalamic-pituitary-adrenal axis activation at P20 were more pronounced in female than male mice. These sex differences could have contributed to the increased susceptibility of female mice to the detrimental long-term cognitive effects of MA and the H3/H4 antagonist thioperamide. Following behavioral testing, mice neonatally treated with MA or thioperamide showed reduced levels of the dendritic marker microtubule-associated protein 2 in the CA3 region of the hippocampus and the enthorhinal cortex. This was not seen in mice neonatally treated with immepip and MA who did not show cognitive impairments, suggesting that these brain areas might be particularly important for the long-term effects of MA on cognitive function. These data support a role for histamine in the effects of MA on the developing brain.
authors.affiliation: Department of Behavioral Neuroscience, Oregon Health and Science University, Portland, Oregon 97239, USA.
authors.forename: Summer F
authors.initials: SF
authors.lastname: Acevedo
authors.forename: Timothy
authors.initials: T
authors.lastname: Pfankuch
authors.forename: Peter
authors.initials: P
authors.lastname: van Meer
authors.forename: Jacob
authors.initials: J
authors.lastname: Raber
mesh_terms: D000367:Age Factors; D000818:Animals; D000831:Animals, Newborn; D001921:Brain / Q000033:anatomy & histology / Q000187:drug effects* / Q000254:growth & development*; D000697:Central Nervous System Stimulants / Q000494:pharmacology*; D003345:Corticosterone / Q000378:metabolism; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005260:Female; D006632:Histamine / Q000378:metabolism*; D054828:Histamine H3 Antagonists / Q000494:pharmacology; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects; D007093:Imidazoles / Q000494:pharmacology; D008297:Male; D008694:Methamphetamine / Q000097:blood / Q000494:pharmacology*; D051379:Mice; D008810:Mice, Inbred C57BL; D008869:Microtubule-Associated Proteins / Q000378:metabolism; D010880:Piperidines / Q000494:pharmacology; D010913:Pituitary-Adrenal System / Q000187:drug effects; D012737:Sex Factors; D013997:Time Factors
chemical_list: D000697:Central Nervous System Stimulants; D054828:Histamine H3 Antagonists; D007093:Imidazoles; D008869:Microtubule-Associated Proteins; C079240:Mtap2 protein, mouse; D010880:Piperidines; C085755:4-(1H-imidazol-4-ylmethyl)piperidine; D008694:Methamphetamine; D006632:Histamine; C052075:thioperamide; D003345:Corticosterone
references.citation: Psychiatry Res. 2004 Dec 15;132(2):95-106
references.pmid: 15598544
references.citation: Neuropsychopharmacology. 2007 Mar;32(3):665-72
references.pmid: 16710318
references.citation: Eur J Pharmacol. 1998 Dec 4;362(2-3):149-55
references.pmid: 9874165
references.citation: Acta Paediatr. 1996 Feb;85(2):204-8
references.pmid: 8640051
references.citation: J Neurochem. 1980 Jun;34(6):1609-13
references.pmid: 6103919
references.citation: Neuroscience. 1989;28(3):585-610
references.pmid: 2710333
references.citation: Exp Brain Res. 1997 Mar;113(3):509-19
references.pmid: 9108217
references.citation: Science. 2004 Aug 27;305(5688):1295-8
references.pmid: 15272123
references.citation: Brain Res Dev Brain Res. 1995 Jul 14;87(2):101-10
references.pmid: 7586491
references.citation: Behav Neurosci. 1992 Jun;106(3):447-56
references.pmid: 1616611
references.citation: Methods Find Exp Clin Pharmacol. 1997 Jun;19(5):289-98
references.pmid: 9379777
references.citation: Proc Soc Exp Biol Med. 1962 Apr;109:937-41
references.pmid: 14498045
references.citation: J Comp Neurol. 1998 Apr 27;394(1):127-37
references.pmid: 9550146
references.citation: J Neurochem. 1981 Mar;36(3):1137-41
references.pmid: 6259281
references.citation: Neurotoxicol Teratol. 2001 Jul-Aug;23(4):349-54
references.pmid: 11485837
references.citation: J Anal Toxicol. 2002 Oct;26(7):513-8
references.pmid: 12423009
references.citation: Neurotoxicol Teratol. 1996 Mar-Apr;18(2):135-9
references.pmid: 8709924
references.citation: Int J Dev Neurosci. 2004 Aug-Oct;22(5-6):273-83
references.pmid: 15380827
references.citation: Nature. 1982 Jun 24;297(5868):681-3
references.pmid: 7088155
references.citation: Science. 2004 Aug 27;305(5688):1258-64
references.pmid: 15333832
references.citation: Neurotoxicol Teratol. 2008 Jan-Feb;30(1):20-8
references.pmid: 18031987
references.citation: Endocrinology. 1991 Mar;128(3):1385-95
references.pmid: 1847856
references.citation: Toxicol Appl Pharmacol. 2005 Dec 15;209(3):203-13
references.pmid: 15916788
references.citation: J Comp Neurol. 1994 Sep 1;347(1):101-14
references.pmid: 7798375
references.citation: JAMA. 2000 May 3;283(17):2225-6
references.pmid: 10807367
references.citation: Neuropsychopharmacology. 2004 Apr;29(4):705-17
references.pmid: 14735131
references.citation: J Neurosci. 1999 Jun 15;19(12):4867-80
references.pmid: 10366621
references.citation: Tohoku J Exp Med. 2001 Dec;195(4):197-217
references.pmid: 11908822
references.citation: Eur J Pharmacol. 1998 Dec 18;363(2-3):93-101
references.pmid: 9881573
references.citation: Brain Res. 1996 Apr 15;716(1-2):29-38
references.pmid: 8738217
references.citation: Biol Psychol. 2005 Apr;69(1):113-32
references.pmid: 15740829
references.citation: Psychopharmacology (Berl). 1997 Apr;130(4):362-7
references.pmid: 9160852
references.citation: Neurotoxicol Teratol. 2000 Sep-Oct;22(5):751-9
references.pmid: 11106868
references.citation: Endocrinology. 2000 May;141(5):1593-8
references.pmid: 10803566
references.citation: Brain Res Bull. 1993;31(1-2):129-34
references.pmid: 8095840
references.citation: Dev Med Child Neurol. 1993 Sep;35(9):798-805
references.pmid: 8354431
references.citation: Science. 1969 Dec 5;166(3910):1301-3
references.pmid: 5388977
references.citation: J Comp Neurol. 1988 Oct 8;276(2):289-303
references.pmid: 3220984
references.citation: Ann N Y Acad Sci. 2004 Oct;1025:257-66
references.pmid: 15542725
references.citation: Nihon Shinkei Seishin Yakurigaku Zasshi. 2002 Jun;22(3):73-8
references.pmid: 12166087
references.citation: Nature. 1983 Apr 28;302(5911):832-7
references.pmid: 6188956
references.citation: Psychopharmacology (Berl). 2003 Jul;168(3):329-38
references.pmid: 12684734
references.citation: Mol Cell Neurosci. 2003 Nov;24(3):614-22
references.pmid: 14664812
references.citation: J Neurochem. 2007 Oct;103(1):124-30
references.pmid: 17573822
references.citation: Psychopharmacology (Berl). 1994 Apr;114(3):392-401
references.pmid: 7855197
references.citation: Synapse. 2003 Jun 1;48(3):138-48
references.pmid: 12645039
references.citation: J Dev Behav Pediatr. 1992 Apr;13(2):108-11
references.pmid: 1577955
references.citation: Trends Neurosci. 1997 Feb;20(2):78-84
references.pmid: 9023876